Literature DB >> 12100163

Reciprocal alterations of Th1/Th2 function in gammadelta T-cell subsets of human immunodeficiency virus-1-infected patients.

Thomas S Dobmeyer1, Rita Dobmeyer, Daniela Wesch, Eilke B Helm, Dieter Hoelzer, Dieter Kabelitz.   

Abstract

While T cells that express Vgamma9 as a variable T-cell receptor chain dominate among peripheral blood gammadelta T cells in healthy adults, Vdelta1 cells are the major subpopulation of gammadelta T cells in human immunodeficiency virus (HIV)-infected patients. We used intracellular cytokine staining and flow cytometry to analyse whether an imbalance of T helper 1 (Th1)/T helper 2 (Th2) cytokine patterns, as observed in alphabeta T cells, also occurs in gammadelta T cells. When compared with healthy HIV-negative subjects, HIV+ patients had a decreased number of interferon-gamma (IFN-gamma)+gammadelta T cells, which showed a linear relation to the CD4+ cell count but not to the plasma viral load. Similar results were obtained when Vgamma9 cells were analysed. In contrast, in the Vdelta1 subpopulation, the number of IFN-gamma+ cells was increased in HIV+ donors when compared with healthy subjects. Even though less impressive, the number of interleukin 4 (IL-4)- and IL-10-producing cells was uniformly inversely correlated with the number of tumour necrosis factor-alpha+ and IFN-gamma+ cells. The increased IFN-gamma-producing capacity of Vdelta1 cells might represent a compensatory mechanism for the progressive loss of Vgamma9 gammadelta T cells during the course of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100163     DOI: 10.1046/j.1365-2141.2002.03555.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Vgamma2Vdelta2+ T cells and anti-microbial immune responses.

Authors:  Zheng W Chen; Norman L Letvin
Journal:  Microbes Infect       Date:  2003-05       Impact factor: 2.700

Review 2.  Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity.

Authors:  Marc Bonneville; Rebecca L O'Brien; Willi K Born
Journal:  Nat Rev Immunol       Date:  2010-06-11       Impact factor: 53.106

Review 3.  Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications.

Authors:  Ilan Bank; Victoria Marcu-Malina
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

4.  Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections.

Authors:  David A Kosub; Ginger Lehrman; Jeffrey M Milush; Dejiang Zhou; Elizabeth Chacko; Amanda Leone; Shari Gordon; Guido Silvestri; James G Else; Philip Keiser; Mamta K Jain; Donald L Sodora
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

5.  Increased frequency of systemic pro-inflammatory Vδ1+ γδ T cells in HIV elite controllers correlates with gut viral load.

Authors:  Gregory S Olson; Sarah W Moore; James M Richter; John J Garber; Brittany A Bowman; Crystal A Rawlings; Meaghan Flagg; Björn Corleis; Douglas S Kwon
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

Review 6.  γδ T-cell responses during HIV infection and antiretroviral therapy.

Authors:  Jennifer A Juno; Emily M Eriksson
Journal:  Clin Transl Immunology       Date:  2019-07-17

Review 7.  Antiviral reactivities of gammadelta T cells.

Authors:  Fabrizio Poccia; Chiara Agrati; Federico Martini; Maria Rosaria Capobianchi; Marianne Wallace; Miroslav Malkovsky
Journal:  Microbes Infect       Date:  2005-03-03       Impact factor: 2.700

8.  CD3ε Expression Defines Functionally Distinct Subsets of Vδ1 T Cells in Patients With Human Immunodeficiency Virus Infection.

Authors:  Pádraic J Dunne; Christina O Maher; Michael Freeley; Katie Dunne; Andreea Petrasca; Judy Orikiiriza; Margaret R Dunne; Derval Reidy; Siobhan O'Dea; Aisling Loy; Jim Woo; Aideen Long; Thomas R Rogers; Fiona Mulcahy; Derek G Doherty
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.